138 related articles for article (PubMed ID: 11040343)
1. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide.
Di Marzo V; Breivogel C; Bisogno T; Melck D; Patrick G; Tao Q; Szallasi A; Razdan RK; Martin BR
Eur J Pharmacol; 2000 Oct; 406(3):363-74. PubMed ID: 11040343
[TBL] [Abstract][Full Text] [Related]
2. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.
Di Marzo V; Lastres-Becker I; Bisogno T; De Petrocellis L; Milone A; Davis JB; Fernandez-Ruiz JJ
Eur J Pharmacol; 2001 May; 420(2-3):123-31. PubMed ID: 11408034
[TBL] [Abstract][Full Text] [Related]
3. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.
Di Marzo V; Griffin G; De Petrocellis L; Brandi I; Bisogno T; Williams W; Grier MC; Kulasegram S; Mahadevan A; Razdan RK; Martin BR
J Pharmacol Exp Ther; 2002 Mar; 300(3):984-91. PubMed ID: 11861807
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross RA; Gibson TM; Brockie HC; Leslie M; Pashmi G; Craib SJ; Di Marzo V; Pertwee RG
Br J Pharmacol; 2001 Feb; 132(3):631-40. PubMed ID: 11159715
[TBL] [Abstract][Full Text] [Related]
5. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
Brooks JW; Pryce G; Bisogno T; Jaggar SI; Hankey DJ; Brown P; Bridges D; Ledent C; Bifulco M; Rice AS; Di Marzo V; Baker D
Eur J Pharmacol; 2002 Mar; 439(1-3):83-92. PubMed ID: 11937096
[TBL] [Abstract][Full Text] [Related]
6. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.
Di Marzo V; Bisogno T; De Petrocellis L; Brandi I; Jefferson RG; Winckler RL; Davis JB; Dasse O; Mahadevan A; Razdan RK; Martin BR
Biochem Biophys Res Commun; 2001 Feb; 281(2):444-51. PubMed ID: 11181068
[TBL] [Abstract][Full Text] [Related]
7. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
8. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
9. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
10. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Di Marzo V; Breivogel CS; Tao Q; Bridgen DT; Razdan RK; Zimmer AM; Zimmer A; Martin BR
J Neurochem; 2000 Dec; 75(6):2434-44. PubMed ID: 11080195
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.
White R; Ho WS; Bottrill FE; Ford WR; Hiley CR
Br J Pharmacol; 2001 Oct; 134(4):921-9. PubMed ID: 11606334
[TBL] [Abstract][Full Text] [Related]
13. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
de Lago E; de Miguel R; Lastres-Becker I; Ramos JA; Fernández-Ruiz J
Brain Res; 2004 May; 1007(1-2):152-9. PubMed ID: 15064146
[TBL] [Abstract][Full Text] [Related]
14. Effect of arvanil (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide-capsaicin hybrid, on ion currents in NG108-15 neuronal cells.
Lo YK; Chiang HT; Wu SN
Biochem Pharmacol; 2003 Feb; 65(4):581-91. PubMed ID: 12566085
[TBL] [Abstract][Full Text] [Related]
15. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases.
Veldhuis WB; van der Stelt M; Wadman MW; van Zadelhoff G; Maccarrone M; Fezza F; Veldink GA; Vliegenthart JF; Bär PR; Nicolay K; Di Marzo V
J Neurosci; 2003 May; 23(10):4127-33. PubMed ID: 12764100
[TBL] [Abstract][Full Text] [Related]
17. Interactions between synthetic vanilloids and the endogenous cannabinoid system.
Di Marzo V; Bisogno T; Melck D; Ross R; Brockie H; Stevenson L; Pertwee R; De Petrocellis L
FEBS Lett; 1998 Oct; 436(3):449-54. PubMed ID: 9801167
[TBL] [Abstract][Full Text] [Related]
18. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
[TBL] [Abstract][Full Text] [Related]
19. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
20. Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats.
Trezza V; Vanderschuren LJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):343-50. PubMed ID: 18948500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
